Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 25;13(13):3650-3661.
doi: 10.1039/d5bm00204d.

Engineering blood-brain barrier microphysiological systems to model Alzheimer's disease monocyte penetration and infiltration

Affiliations

Engineering blood-brain barrier microphysiological systems to model Alzheimer's disease monocyte penetration and infiltration

Longjun Gu et al. Biomater Sci. .

Abstract

Alzheimer's disease (AD) is a progressive and neurodegenerative disease, predominantly causing dementia. Despite increasing clinical evidence suggesting the involvement of peripheral immune cells such as monocytes in AD pathology, the dynamic penetration and infiltration of monocytes crossing blood-brain barrier (BBB) and inducing neuroinflammation is largely understudied in an AD brain. Herein, we engineer BBB-like microphysiological system (BBB-MPS) models for recapitulating the dynamic penetration and infiltration of monocytes in an AD patient's brain. Each BBB-MPS model can be engineered by integrating a functional BBB-like structure on a human cortical organoid using a 3D-printed device within a well of a plate. By coculturing these BBB-MPS models with monocytes from AD patients and age-matched healthy donors, we found that AD monocytes exhibit significantly greater BBB penetration and brain infiltration compared to age-matched control monocytes. Moreover, we also tested the interventions including Minocycline and Bindarit, and found they can effectively inhibit AD monocyte infiltration, subsequently reducing neuroinflammation and neuronal apoptosis. We believe these scalable and user-friendly BBB-MPS models may hold promising potential in modeling and advancing therapeutics for neurodegenerative and neuroinflammatory diseases.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70. Epub 2017/09/06. doi: 10.1111/ene.13439. - DOI - PubMed
    1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14(1):32. Epub 2019/08/04. doi: 10.1186/s13024-019-0333-5. - DOI - PMC - PubMed
    1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90. Epub 2021/03/06. doi: 10.1016/S0140-6736(20)32205-4. - DOI - PMC - PubMed
    1. Dallemagne P, Rochais C. Facing the complexity of Alzheimer’s disease. Future Med Chem. 2020;12(3):175–7. Epub 2019/11/22. doi: 10.4155/fmc-2019-0310. - DOI - PubMed
    1. Bettcher BM, Tansey MG, Dorothee G, Heneka MT. Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. Nat Rev Neurol 2021;17(11):689–701. Epub 2021/09/16. doi: 10.1038/s41582-021-00549-x. Association and a consultant to INmune Bio. G.D. is listed as an inventor on patent WO2014206899A1 related to a peripheral immunomodulatory approach for treating Alzheimer disease and related disorders, and on patent WO2018172540A1 related to peripheral immune biomarkers for predicting the progression of Alzheimer disease. The other authors declare no competing interests. - DOI - PMC - PubMed

LinkOut - more resources